← SynDRA
CILASTATIN
SynDRA canonical compound SYN0001762 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | DPEP1 |
|---|
| Mechanism of action | dehydropeptidase inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- DPEP1 INHIBITOR
- Renal dipeptidase inhibitor
- dehydropeptidase inhibitor
Drug classes
- Dipeptidase Inhibitors
- Renal Dehydropeptidase Inhibitor
- Enzyme Inhibitors
- Protease Inhibitors
- Anti-Bacterial Agents
ATC classes
- OTHER BETA-LACTAM ANTIBACTERIALS
Cross-references
Synonyms
- cilastatin sodium
- cilastin
- cilastatin monosodium
- Cilastatine
- Cilastatina
- PRIMAXIN
- Cilastatinum
- Cilastatin Monosodium Salt
- Cilastatin acid
- Cilastatina [Spanish]
- Cilastatine [French]
- Cilastatinum [Latin]
- MK0791
- Cilastatin (INN)
- Cilastatin [INN:BAN]
- MK-791
- (2Z)-7-{[(2R)-2-amino-2-carboxyethyl]sulfanyl}-2-({[(1S)-2,2-dimethylcyclopropyl]carbonyl}amino)hept-2-enoic acid
- (Z)-(S)-6-carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine
- (Z)-7-[(2R)-2-amino-3-hydroxy-3-oxopropyl]sulfanyl-2-[[(1S)-2,2-dimethylcyclopropanecarbonyl]amino]hept-2-enoic acid
- MK 791
- CHEBI:3697
- MK791
- RefChem:126129
- DTXCID3028213
- MFCD00867379
- CILASTATIN [INN]
- MK 0791
- C16H26N2O5S
- Cilastin
- NCGC00181346-01
- EINECS 279-875-8
- Cilastastin
- UNII-141A6AMN38
- Cilastatin (Standard)
- CILASTATIN [MI]
- CILASTATIN [VANDF]
- CILASTATIN [WHO-DD]
- SCHEMBL37051
Reported adverse events
- Headache
- Nausea
- Rash
- Seizure
- Vomiting
- Agitation
- Cyanosis
- Dizziness
- Dyskinesia
- Erythema
- Flushing
- Glossitis
Look up CILASTATIN in the interactive SynDRA portal →